↓ Skip to main content

First-in-Human Phase 1 Study of MORAb-202, an Antibody–Drug Conjugate Comprising Farletuzumab Linked to Eribulin Mesylate, in Patients with Folate Receptor-α–Positive Advanced Solid Tumors

Overview of attention for article published in Clinical Cancer Research, April 2021
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • High Attention Score compared to outputs of the same age (91st percentile)
  • High Attention Score compared to outputs of the same age and source (87th percentile)

Mentioned by

news
3 news outlets
twitter
11 tweeters

Citations

dimensions_citation
8 Dimensions

Readers on

mendeley
15 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
First-in-Human Phase 1 Study of MORAb-202, an Antibody–Drug Conjugate Comprising Farletuzumab Linked to Eribulin Mesylate, in Patients with Folate Receptor-α–Positive Advanced Solid Tumors
Published in
Clinical Cancer Research, April 2021
DOI 10.1158/1078-0432.ccr-20-4740
Pubmed ID
Authors

Toshio Shimizu, Yutaka Fujiwara, Kan Yonemori, Takafumi Koyama, Jun Sato, Kenji Tamura, Akihiko Shimomura, Hiroki Ikezawa, Maiko Nomoto, Keiji Furuuchi, Ryo Nakajima, Takuma Miura, Noboru Yamamoto

Twitter Demographics

The data shown below were collected from the profiles of 11 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 15 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 15 100%

Demographic breakdown

Readers by professional status Count As %
Other 3 20%
Researcher 2 13%
Student > Bachelor 1 7%
Student > Ph. D. Student 1 7%
Professor 1 7%
Other 0 0%
Unknown 7 47%
Readers by discipline Count As %
Pharmacology, Toxicology and Pharmaceutical Science 4 27%
Medicine and Dentistry 2 13%
Nursing and Health Professions 1 7%
Biochemistry, Genetics and Molecular Biology 1 7%
Unknown 7 47%

Attention Score in Context

This research output has an Altmetric Attention Score of 26. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 27 June 2022.
All research outputs
#1,168,837
of 21,425,694 outputs
Outputs from Clinical Cancer Research
#813
of 12,198 outputs
Outputs of similar age
#29,978
of 338,168 outputs
Outputs of similar age from Clinical Cancer Research
#23
of 179 outputs
Altmetric has tracked 21,425,694 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 94th percentile: it's in the top 10% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 12,198 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 10.2. This one has done particularly well, scoring higher than 93% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 338,168 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 91% of its contemporaries.
We're also able to compare this research output to 179 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 87% of its contemporaries.